The two novel antibiotics, ceftolozane/tazobactam (ceftol-tazo) and ceftazidime/avibactam (ca-avi), have been used in few “real-life” experiences for treatment of such infections with reported clinical and microbiological success in patients with hematological malignancies, although data are currently scarce and based mainly on case series and case reports.
In order to better define the role of these drugs in hematological cancer patients, this research project proposes you a multicentre nationwide study by SEIFEM on real-life experience with ceftol-tazo or caz-avi in patients with hematologic malignancy.
In this retrospective/prosepective study (jan 2019-dec 2021) all patients with hematologic malignancy treated for empirical or target therapy)with celtol-tazo or caz-avi in the post-marketing phase will be included.